Methylphenidate 18, 27, 36 & 54 Drl 18, 27, 36 & 54 mg Prolonged-release tablets
PDF Leaflet Revision Date: 08 April 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of ADHD in children, adolescents, and adults.
Dosage (summary)
Starting dose: 18 mg once daily for children/adolescents; 18 or 36 mg for adults. Max: 54 mg/day for children, 72 mg for adolescents, 108 mg for adults.
Onset of Action / Duration
Onset: 1-2 hours, Duration: 12 hours
Special Populations
- Elderly
- Children under 6 years
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- MAO inhibitors
- Antihypertensives
- Serotonergic medicines
Contraindications
- Hypersensitivity to methylphenidate
- Glaucoma
- Pheochromocytoma
- Severe depression
- Cardiovascular disorders
Common side effects
- Insomnia
- Nervousness
- Decreased appetite
- Headache
- Dizziness
Counselling Points
- Take in the morning
- Swallow whole with water
- Monitor for mood changes
- Avoid alcohol
Serious warnings
- Risk of sudden death in patients with cardiac abnormalities
- Potential for abuse and dependence
- Emergence of psychiatric symptoms
Important Disclaimer
The Methylphenidate 18, 27, 36 & 54 Drl 18, 27, 36 & 54 mg Prolonged-release tablets professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
